Emma Rooth to Helm PCCA UK, Steering Personalized Medicine's Future

PRUDHOE, UK – January 27, 2026 – Precision Health Holdings has appointed veteran life sciences executive Emma Rooth as the new Chief Executive Officer of PCCA UK, a strategic move poised to accelerate the company's growth in the burgeoning personalized medicine sector. Rooth, who officially stepped into the role on January 6, 2026, brings a formidable track record of business transformation and international expansion, signaling a new era of ambition for the UK-based pharmaceutical innovator.

The appointment comes at a pivotal moment for personalized healthcare, a field that tailors medical treatment to the individual characteristics of each patient. PCCA UK, a key player in this space, specializes in pharmaceutical compounding—creating customized medications, or "specials," for patients whose needs cannot be met by mass-produced drugs. With Rooth at the helm, the company is set to deepen its impact across the United Kingdom and Europe.

A Legacy of Transformative Leadership

Emma Rooth is not just a new executive; she is a recognized architect of growth and change. With over 25 years of leadership experience, her career is marked by a series of high-impact roles across the healthcare and pharmaceutical industries. Her recent recognition as the 'Inspiring Change Leader of the Year 2024' at the Women in Change Awards underscores her reputation as a dynamic and effective leader.

Her most notable success was her eight-year tenure as CEO of Torbay Pharmaceuticals. There, she orchestrated a profound transformation, evolving the company from a UK-focused entity into a leading international contract manufacturing organization (CMO). A key part of this journey was navigating the complex transition of the business from National Health Services (NHS) ownership to the portfolio of private equity firm NorthEdge. This shift required not only sharp commercial acumen but also a deep understanding of organizational culture and strategic repositioning. Under her guidance, Torbay expanded its global footprint and, critically, achieved FDA inspection readiness—a rigorous benchmark of quality and operational excellence that opened doors to the lucrative U.S. market.

“Emma brings a rare combination of strategic vision, operational leadership and deep understanding of UK and European healthcare markets,” said Jim Smith, Chief Executive Officer of Precision Health Holdings, the strategic holding company of PCCA UK. “She is a proven leader with a strong record of building teams, expanding market presence and leading organisations through periods of growth. We are confident she is the right leader to build on PCCA UK’s strong foundation and lead the company into its next phase.”

Before her transformative role at Torbay, Rooth honed her skills in senior positions at BUPA UK, where she served as Commercial Director for the public sector, and at AAH Pharmaceuticals, where she was Director of Business Development. Her experience spans change management, revenue scaling, and forging public-private sector partnerships, a skillset directly applicable to the challenges and opportunities facing PCCA UK.

Capitalizing on a Booming Market

Rooth’s appointment is a calculated move to capitalize on the explosive growth within the personalized medicine market. The sector is no longer a niche corner of healthcare but a rapidly expanding frontier. In the UK alone, the personalized medicine market generated nearly $22 billion in 2024 and is projected to more than double, reaching over $47 billion by 2033, reflecting a compound annual growth rate (CAGR) of 9%. The wider European market is even larger, valued at over $166 billion in 2024.

This growth is fueled by scientific breakthroughs in genomics, the integration of AI-driven diagnostics, and a fundamental shift towards patient-centric care. PCCA UK operates at the very heart of this trend. The company, which holds a Manufacturing Specials (MS) License from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA), produces customized non-sterile medications in compliance with Good Manufacturing Practices (cGMP). These "specials" are vital for patients who may need specific dosages, be allergic to common ingredients in licensed drugs, or require a different form of medication, such as a liquid instead of a pill.

Navigating this landscape requires a leader who understands not only the commercial opportunities but also the complex regulatory environment. Rooth's success in achieving FDA readiness at Torbay demonstrates her proficiency in meeting the highest international quality standards, a crucial asset as PCCA UK looks to expand its services and influence across different European regulatory systems.

A Strategic Play by Precision Health Holdings

The decision to bring in a leader of Rooth's caliber underscores the strategic importance of PCCA UK to its parent company, Precision Health Holdings. The holding company's mission is to make personalized medicine a standard of care globally by uniting and empowering a family of healthcare innovators. By providing capital, shared leadership, and strategic alignment, it aims to create an integrated enterprise that drives innovation and value.

Rooth's experience in managing a private equity transition is particularly relevant. While PCCA UK is a subsidiary of a holding company, her ability to deliver value, streamline operations, and drive growth is precisely what investors and strategic owners look for. Her appointment signals that Precision Health Holdings is investing heavily in PCCA UK's future, positioning it as a cornerstone of its European strategy. The goal is not just to maintain market position but to aggressively expand it, leveraging PCCA UK's 40-year heritage of quality and innovation.

“I am honoured to join PCCA UK at such an exciting time,” Rooth stated. “PCCA has a strong reputation for quality, innovation and partnership across the compounding and personalised medicine landscape. I look forward to working with the team to build on that legacy, strengthen relationships with our partners and support the evolving needs of patients and healthcare professionals across the UK and Europe.”

Her focus on strengthening relationships with partners—including pharmacies, hospitals, clinics, and healthcare professionals—will be critical. As personalized medicine becomes more integrated into mainstream healthcare, the ability to collaborate effectively across the ecosystem will define the market leaders. Rooth's appointment is a clear statement of intent that PCCA UK plans to be at the forefront of that movement, driving the next wave of patient-centric care.